Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nuvelo has announced positive results from the Phase III NAPA or novel arterial perfusion with alfimeprase program evaluating alfimeprase in acute peripheral arterial occlusion.
Subscribe to our email newsletter
In the NAPA-2 clinical trial, the primary endpoint of 30-day open vascular surgery avoidance was achieved in 34.9% of patients receiving alfimeprase, 37.2% of patients receiving intra-thrombus (IT) placebo, and 18.4% of patients receiving peri-thrombus (PT) placebo. An interim analysis of the NAPA-3 study shows that 30-day open vascular surgery avoidance was achieved in 29.4% of patients receiving alfimeprase and 17.6% of patients receiving IT placebo. However, serious adverse events (SAE), major hemorrhage, cardiac events and infections were higher in subjects receiving alfimeprase in NAPA-2, but were higher in subject receiving IT placebo in NAPA-3.
Efficacy data from subjects with longer clots or smaller drops in alpha-2 macroglobulin, which rapidly and irreversibly inactivates alfimeprase, suggest improved retention of alfimeprase at the site of the clot might improve lysis.